Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

Recruiting now · Phase 2

Conditions studied: Warts, Human Papilloma Virus

In brief

To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy

Key facts

Study ID

NCT05291845

Run by

Zagazig University

People needed

162

Starts

2022-04-03

Expected to finish

2025-12-06

Last updated by the study team

2025-06-12

Who can join

Age: 9 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients with multiple, recalcitrant, or non-recalcitrant common warts of different sites, sizes, duration, and with or without distant lesions will be enrolled in the study

You may not qualify if…

• Pregnant female. Hypersensitivity to Candida antigen or bivalent HPV vaccine

Where it is running

• Reham Essam — Zagazig, Al Sharqia, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.